Contact: Dennis J. Curtin, Chief Financial Officer
Telephone: 1-800-544-4624, ext. 320

E-Z-EM, INC., Reports Results for Second Quarter 2002

Westbury, New York; January 15, 2002 E-Z-EM, Inc., (AMEX - EZM.A and EZM.B) today announced 
results for the second fiscal quarter ended December 1, 2001. The Company reported a net loss 
of $1,167,000, ($.12) per share, on net sales of $30,629,000 after restructuring charges were 
taken in the second quarter. Without these charges, the Company would have reported earnings 
of $365,000, or $.04 per share. In the second quarter of fiscal 2001, the Company announced 
net earnings of $861,000, $.09 and $.08 per share on a basic and diluted basis, respectively, 
on net sales of $26,658,000. 

The Company reported a net loss for the first six months of fiscal 2002 of $1,279,000, ($.13) 
per share, on net sales of $58,270,000. Without restructuring charges, the Company would have 
reported net earnings of $253,000, or $.03 per share. In the comparable period last year, the 
Company had net earnings of $2,703,000 on net sales of $54,391,000. Basic and diluted earnings 
were $.27 and $.26 per share, respectively. 

Results for the quarter and year-to-date were impacted by restructuring costs of $1,532,000 
related to the decision to close the Company’s Japanese manufacturing facility in December 2001 
and focus on the growing sales of contrast systems manufactured in the U.S. and imported into 
the large Japan market. The restructuring charge impacted earnings for the quarter and the year 
by $.16 per share. In last year’s quarter several factors combined to have a favorable effect 
on net earnings of $418,000, or $.04 per basic share. Last year’s results included the reversal 
of a tax valuation allowance of $1,344,000. Partially offsetting this was the write-down of 
$450,000 for acquired patent rights to an oral MRI contrast agent, and a loss of $872,000 
from the sale of a manufacturing facility in the Republic of Ireland owned by the Company’s 
AngioDynamics subsidiary. 

Commenting on the Company’s results, Anthony A. Lombardo, E-Z-EM’s President and CEO said, "We 
are on track to streamline E-Z-EM and position it for growth, and the restructuring decisions 
are part of our strategic plan to realign the Company. Our AngioDynamics subsidiary continued 
its strong growth, with net sales increasing 41% for the quarter and 26% for the six months. 
This increase in sales was fueled by domestic growth in vascular access products, angiographic 
catheters and stent/angioplasty products. Our decision to focus on the rapidly expanding 
interventional radiology area, and our continued investments in sales force support and new 
product lines, are resulting in double-digit growth in the AngioDynamics segment. Despite these 
investments, AngioDynamics’ operating profit for the quarter increased $460,000, or 146%, from 
last year’s comparable quarter and by $1,215,000 compared to the first six months of 2001, 
which included the loss on the sale of the Irish facility. 

"Operating results for our Diagnostic segment were on plan and were impacted by the closure of 
our Japanese manufacturing facility and by investments the Company continues to make in new 
product segments and sales force expansion. The Company recently introduced new products, 
including the EmpowerCT(TM) contrast injector, InnerviewGI(TM), a software-based system for 
virtual colonoscopy, and NutraPrep(TM), a revolutionary system for bowel preparation that 
removes patient compliance issues in both optical colonoscopy and radiology exams of the GI 
tract. These products are helping position the Company as the premier supplier of systems for 
CT contrast delivery as well as for virtual colonoscopy. The Company’s joint venture with 
O’Dell Engineering in the area of decontamination for both biological and chemical agents 
continues to receive strong response from various domestic and foreign government agencies. 
The Diagnostic division has growth rates for CT contrast agents in double-digit levels, and 
has launched a new product line for evaluating swallowing disorders - the Dysphagia market 
segment - that has shown promising growth since introduction in the fourth quarter of 2001." 

About E-Z-EM, Inc. 

E-Z-EM is the world’s largest manufacturer of contrast agents for gastrointestinal radiology. 
The Company’s wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, 
including angiographic, vascular access, thrombolytic, angioplasty, stents, as well as 
abdominal infection drainage products. AngioDynamics’ focus is on diagnostic and therapeutic 
products for interventional radiology and other areas of minimally invasive surgery. Enteric 
Products, Inc., another subsidiary, develops, manufactures and markets tests for detection of 
the ulcer- and cancer-causing bacterium Helicobacter pylori. For additional information, 
please contact Frank Kerrigon at 1-800-544-4624, ext. 325, (Email: fkerrigon@ezem.com) or 
visit our corporate web site at www.ezem.com. 

The statements made in this document contain certain forward looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans",
"believes", "seeks", "estimates", or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited 
to its Form 10-Q for the quarter ended December1, 2001, as well as its Annual Report on Form 
10-K for the year ended June 2, 2001, may affect the actual results achieved by the Company.

End